Results from the clinical trial at Texas A&M indicate the treatment could be useful in treating glioblastoma, an aggressive form of brain cancer found in humans.
To improve the efficacy of immunotherapies, a Texas A&M team uses nanoparticles to change the environment inside a tumor, giving immune cells the upper hand.
Astatine-211, a candidate for targeted alpha-particle therapy, decays in hours. Researchers have delineated a purification process that can extract it in minutes, increasing the amount of the element available for use.